Overview

A Trial to Investigate Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BioChaperone® Pramlintide Insulin in Patients With Type 1 Diabetes Mellitus

Status:
Completed

Trial end date:
2019-02-14

Target enrollment:

Participant gender:

Summary

This is a single center, randomised, double-blind, active comparator controlled, three-period cross-over, single dose trial in subjects with type 1 diabetes mellitus.

Phase:

Phase 1

Details

Lead Sponsor:

Adocia

Treatments:

Insulin
Insulin Lispro
Insulin, Globin Zinc
Islet Amyloid Polypeptide
Pramlintide